$AMMX- Analysts Report- 8 Quarters of PROFIT$$$$$-

New Post Public Reply Private Reply Replies (0) Message Board
$maker
$AMMX- Analysts Report- 8 Quarters of PROFIT$$$$$- UNDERVALUED, Major News Coming

Summary of Our Research Findings

This report offers an analysis of AmeraMex International, Inc., which trades as AMMX on the OTC.
We believe there is a positive risk reward ratio to these shares at the current price.
AmeraMex is a heavy equipment sales, rental and leasing company, located in California, that has reported eight consecutive quarters of profitability.
The Company has developed a specialty in shipping container loading and unloading equipment serving several of the U.S. West Coast port operators.
The trend toward renting and leasing of heavy equipment continues to benefit AMMX’s business.
With a stable U.S. business, the Company is expanding internationally and has developed several very meaningful business opportunities in Western Africa. Should the necessary financing be secured, a very positive affect on revenues should result.
The Company has already preannounced a strong December 2015 quarter and provided guidance for additional growth in the 2016.
We can easily see 40% top line growth for 2016 at revenue of $13mm. Current market cap is only $5 mm yielding an attractive price-to-sales ratio for this growing and profitable company.
Over the coming weeks, we will be watching closely for news relative to the development of the Company’s African opportunities. Should the financing be secured, the price of the shares will likely rise significantly.

http://www.globesmallcap.com/ammx-eight-quart...re-likely/
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Rollins' Current Market Position and Outlook

Updated Category News Views 226

Analyzing Rollins Inc.'s Stock Performance As we look at the current performance of Rollins Inc. (NYSE: ROL), the shares are trading around $55.73, reflecting a decrease of 1.24% in the recent session. While the stock has dipped by 3.81% over the past month, it has impressively increased by 10.91% year-over-year. This presents a curious juxtaposition of short-term...

Continue Reading
Silver One Reports Major Mineral Resource Estimate for Candelaria

Updated Category News Views 199

Candelaria Project Mineral Resource Estimate Silver One Resources Inc. (OTCQX: SLVRF) has made a significant announcement regarding the completion of a mineral resource estimate for the Candelaria Project. This estimate is prepared in accordance with the National Instrument 43-101, ensuring that the resources are assessed with high standards of transparency and accuracy....

Continue Reading
Investors Alert: Zynex (ZYXI) Faces Serious Legal Scrutiny

Updated Category News Views 197

Legal Investigation into Zynex, Inc. The Law Offices of Frank R. Cruz have announced a crucial investigation regarding Zynex, Inc. (ZYXI) focused on potential violations of federal securities laws. This investigation comes as a response to significant concerns raised about the company's recent financial disclosures and their implications for investors. Understanding the...

Continue Reading
Understanding Rentokil Initial's Stock Valuation Insights

Updated Category News Views 100

Assessing Rentokil Initial's Stock Performance In the current trading session, Rentokil Initial Inc. (NYSE: RTO) shares are priced at $26.42, witnessing a notable increase of 1.46%. Over the past month, the stock has gained 1.40%, though it has faced a decline of 7.78% in the last year. This fluctuation raises questions among shareholders regarding its valuation, despite...

Continue Reading
Innovative Insights on Efzofitimod from aTyr Pharma's Recent Conference

Updated Category News Views 177

aTyr Pharma Highlights Efzofitimod at Key Conference At a significant scientific gathering, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology firm known for its innovative therapeutic approaches, shared compelling data concerning efzofitimod. This presentation underlined important insights about the treatment of pulmonary sarcoidosis. The conference, which...

Continue Reading